Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
Abstract Background Chronic migraine (CM) is a highly disabling form of migraine in which patients have ≥ 15 headache days per month, of which at least 8 have the features of migraine. Galcanezumab is a monoclonal antibody to calcitonin gene-related peptide which is approved for the preventive treat...
Saved in:
Main Authors: | Hans-Christoph Diener, Kathleen A. Day, Sarah Lipsius, Sheena K. Aurora, Nada A. Hindiyeh, Holland C. Detke |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | https://doi.org/10.1186/s10194-025-01956-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation
by: Wanakorn Rattanawong, et al.
Published: (2025-01-01) -
Epidemiology of clinically significant migraine in Israel: a retrospective database study
by: A. Shifrin, et al.
Published: (2025-02-01) -
Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
by: Austėja Dapkutė, et al.
Published: (2021-12-01) -
The epidemiology and unmet need of migraine in five european countries: results from the national health and wellness survey
by: Gianluca Coppola, et al.
Published: (2025-01-01) -
The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: Monika Remenčiūtė, et al.
Published: (2024-05-01)